Exhibit 10.2
LICENSE AND COLLABORATION AGREEMENT
BETWEEN
TOPOTARGET A/S
AND
CURAGEN CORPORATION
DATED AS OF June 3, 2004
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential Investment under Rule 24b-2 under the Securities Exchange Act of 1934.
LICENSE AND COLLABORATION AGREEMENT
THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), dated as of June 3, 2004, is between
TopoTarget A/S, a company duly organized and existing under the laws of Denmark and having offices at Symbion Science
Park, Fruebjergvej 3, 2100 Copenhagen, Denmark (“TOPOTARGET”), and CURAGEN Corporation, a company duly organized
and existing under the laws of the State of Delaware and having offices at 555 Long Wharf Drive, New Haven, CT 06511, USA
(“CURAGEN”).
PRELIMINARY STATEMENTS
A. TOPOTARGET is a biotechnology company with a development program, a library of compounds, and other intellectual
property rights relating to HDAC Inhibitors.
B. CURAGEN is a biopharmaceutical company with an interest in commercializing HDAC Inhibitors in the Territory.
C. TOPOTARGET and CURAGEN wish to collaborate in connection with the research, development and commercialization
of TOPOTARGET HDAC Inhibitors, upon the terms and conditions set forth in this Agreement.
D. TOPOTARGET and CURAGEN are willing to grant to each other certain rights owned or controlled by them relating to
HDAC Inhibitors in connection with their collaboration, upon the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the foregoing preliminary statements and the mutual covenants and agreements of
the Parties contained in this Agreement, the Parties hereby agree as follows:
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confi